Paraprevotella Composition for Intestinal Trypsin Suppression in IBD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of identified bacteria capable of effectively suppressing trypsin activity, which is associated with the onset and exacerbation of inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease.
Innovation Solution
Isolation and identification of bacterial strains from the genus Paraprevotella, specifically Paraprevotella clara and Paraprevotella xylaniphila, which are found to significantly reduce trypsin activity in the intestinal tract, along with other bacteria like Parabacteroides merdae and Bacteroides uniformis, through proteolytic enzyme suppression and degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional bacteria are used in the intestine, then normal digestive function is maintained, but trypsin activity remains high and contributes to inflammation in IBD patients
Solution Approach 1:
The patent applies this principle by utilizing the natural proteolytic activity of Paraprevotella bacteria to degrade excess trypsin, which is normally a harmful factor in IBD. The bacteria convert the harmful trypsin activity into a beneficial effect by breaking down the enzyme that causes inflammation, thereby transforming a pathological condition into a therapeutic opportunity.
Solution Approach 2:
Paraprevotella bacteria serve as an intermediary organism between the host and the harmful trypsin. These bacteria mediate the degradation of trypsin through their proteolytic enzymes, acting as a biological intermediary that reduces trypsin activity without directly interacting with the inflammatory pathways, thus providing a indirect but effective therapeutic mechanism for IBD.
2Object-affected harmful factors
If trypsin activity is suppressed to treat IBD, then inflammation is reduced, but few bacterial species are known to perform this function
Solution Approach 1:
The patent extracts and isolates the specific functional capability of trypsin degradation from the complex intestinal microbiota. By identifying and characterizing Paraprevotella species as the specific bacteria capable of suppressing trypsin activity, the invention extracts this therapeutic function from the general microbial community, making it available for targeted therapeutic application.
Solution Approach 2:
The patent changes the parameter of bacterial species composition in the intestine by introducing Paraprevotella species. This parameter change—specifically increasing the population of these trypsin-degrading bacteria—leads to reduced trypsin activity and subsequent anti-inflammatory effects, providing a new therapeutic parameter for IBD treatment.
3Reliability
If Paraprevotella bacteria are introduced to suppress trypsin activity, then therapeutic effect is achieved, but detailed studies on individual bacterial species and host proteins are limited
Solution Approach 1:
The patent performs preliminary action by conducting comprehensive proteomic analysis of intestinal contents before establishing the therapeutic application. This preliminary characterization of host proteins and bacterial interactions provides a foundation for understanding the mechanism of action, reducing the information gap about bacterial-protein interactions while enabling the development of reliable therapeutic strategies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The identified bacterial strains effectively suppress trypsin activity, leading to reduced inflammation and alleviation of IBD symptoms in animal models, providing a potential therapeutic strategy for IBD.
Implementation Method 1
bacteria belonging to the genus Paraprevotella, specifically Paraprevotella clara and Paraprevotella xylaniphila, which significantly reduce trypsin activity by degrading trypsin
Data Source
AI summary
A composition for suppressing trypsin activity is disclosed. The composition contains a bacterium belonging to a genus Paraprevotella as an active ingredient.